Volume 3, Issue 5, September 2014, Page: 130-131
Curative Effect of Botulinum Toxin-A Injection in Myopia Treatment: Two Case Reports
Jianjun Liu, The Children Rehabilitation Department, China Rehabilitation Research Centre, Capital Medical University School of Rehabilitation Medicine, Beijing, China
Shurong Ji, The Children Rehabilitation Department, China Rehabilitation Research Centre, Capital Medical University School of Rehabilitation Medicine, Beijing, China
Received: Aug. 11, 2014;       Accepted: Aug. 26, 2014;       Published: Sep. 10, 2014
DOI: 10.11648/j.cmr.20140305.13      View  2466      Downloads  140
Abstract
Purpose: To study the curative effect of botulinum toxin-A injection in myopia treatment and whether this method can promote the vision of the patients with myopia. Methods: The left visual acuity of a 37 years old woman was improved from 0.5 to 0.8 after cosmetic injection in July 2011. Another 9 years old girl with pseudomyopia was treated by bilateral ciliary injection in September 2012, and the doses were 2.5IU respectively. Results: The woman was true myopia, and her left visual acuity was lasting at 0.8 for 5 months. The left visual acuity of the girl was enhanced from 0.6 to 0.8, and the right was improved from 0.7 to 1.0. And the improvement is for more than 18 months. Conclusions: BTX-A injection can relax the ciliary muscle tension and promote the myopic vision, especially in pseudomyopia patients.
Keywords
Myopia, Pseudomyopia, True Myopia, Botulinum Toxin-A, Ciliary Muscle
To cite this article
Jianjun Liu, Shurong Ji, Curative Effect of Botulinum Toxin-A Injection in Myopia Treatment: Two Case Reports, Clinical Medicine Research. Vol. 3, No. 5, 2014, pp. 130-131. doi: 10.11648/j.cmr.20140305.13
Reference
[1]
Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia. Ophthalmic Physiol Opt 2012; 32(1):3-16.
[2]
Sun J, Zhou J, Zhao P, Lian J, Zhu H, Zhou Y, et al. High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai. Invest Ophthalmol Vis Sci 2012; 53(12):7504-7509.
[3]
Hashemi H, Khabazkhoob M, Jafarzadehpur E, Yekta AA, Emamian MH, Shariati M, et al. High prevalence of myopia in an adult population, Shahroud, Iran. Optom Vis Sci 2012; 89(7):993-999.
[4]
Jung SK, Lee JH, Kakizaki H, Jee D. Prevalence of myopia and its association with body stature and educational level in 19-year-old male conscripts in seoul, South Korea. Invest Ophthalmol Vis Sci 2012; 53(9):5579-5583.
[5]
Pärssinen O. The increased prevalence of myopia in Finland. Acta Ophthalmol 2012; 90(6):497-502.
[6]
Lam CS, Lam CH, Cheng SC, Chan LY. Prevalence of myopia among Hong Kong Chinese schoolchildren: changes over two decades. Ophthalmic Physiol Opt 2012; 32(1):17-24.
[7]
Cooper J, Schulman E, Jamal N. Current status on the development and treatment of myopia. Optometry 2012; 83(5):179-199.
[8]
Jones R. Physiological pseudomyopia. Optom Vis Sci 1990; 67(8):610-616.
[9]
Tarutta EP, Tarasova NA. Accomodation tonus in myopia and its potential prognostic value. Vestn Oftalmol 2012; 128(2):34-37.
[10]
Albavera-Hernandez C, Rodriguez J, Idrovo AJ. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomised clinical trials. Clin Rehabil 2009; 23:394-407.
[11]
Carruthers J, Carruthers A. Botulinum toxin in facial rejuvenation: an update. Obstet Gynecol Clin North Am 2010; 37(4):571-582.
[12]
Lesin M, Bojić L, Romac R, Lesin J, Ivanisević M, Galetović D, et al. Afect of botulinum toxin-A injection on intraocular pressure and proptosis in thyroid associated orbitopathy. Coll Antropol 2009; 33(4):1155-1157.
Browse journals by subject